Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333840 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,106
- Enrollment target
NCT00333840 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,106 participants.
The verdict
NCT00333840, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,106 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.
Interventions
- DRUG imatinib mesilate
- DRUG interferon-alpha (INF-a)
- DRUG cytarabine (ARA-C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,106 participants |
| Start Date | 2000-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333840
The ClinicalTrials.gov registry entry for NCT00333840 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which imatinib mesilate is the first listed.
NCT00333840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333840 about?
NCT00333840 is a clinical study titled "Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia". The purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus...
What is the current status of trial NCT00333840?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,106 participants. The study started on 2000-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00333840?
The interventions under investigation include: imatinib mesilate (DRUG), interferon-alpha (INF-a) (DRUG), cytarabine (ARA-C) (DRUG).
Who is sponsoring clinical trial NCT00333840?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.